KRYS

Krystal Biotech, Inc. (NASDAQ:KRYS) is a biotechnology company founded in 2015 and headquartered in Pittsburgh, Pennsylvania. The company specializes in developing redosable gene therapies for rare diseases, with a particular focus on dermatological conditions. Krystal achieved a significant milestone in 2023 when it became the first company to receive FDA approval for a redosable gene therapy with its lead product VYJUVEK (beremagene geperpavec or B-VEC) for treating dystrophic epidermolysis bullosa. The company has successfully transitioned from a clinical-stage biotechnology firm to a profitable commercial enterprise, generating nearly $291 million in revenue in 2024 from VYJUVEK sales alone.